Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.8% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3326
Motorsport Games
MSGM
$18.1M
| $84.7K | ﹤0.01% |
+29,200
| New | +$69.2K |
|
3327
Skillful Craftsman
EDTK
$14.8M
| $83.7K | ﹤0.01% |
96,700
-13,900
| -13% | -$13.4K |
|
|
RBOT
3328
DELISTED
Vicarious Surgical
RBOT
| $83.5K | ﹤0.01% |
11,134
-1,500
| -12% | -$10.9K |
|
3329
KALA BIO
KALA
$14.1M
| $82.8K | ﹤0.01% |
+348
| New | +$67.9K |
|
3330
CVRx
CVRX
$137M
| $82.3K | ﹤0.01% |
+14,000
| New | +$96.6K |
|
|
GRCE
3331
Grace Therapeutics
GRCE
$33.8M
| $82K | ﹤0.01% |
27,625
-14,556
| -35% | -$38.7K |
|
3332
VistaGen Therapeutics
VTGN
$9.89M
| $81K | ﹤0.01% |
40,500
+15,700
| +63% | +$35.7K |
|
|
YQ
3333
17 Education & Technology Group
YQ
$18.7M
| $80.7K | ﹤0.01% |
36,830
+15,600
| +73% | +$30.2K |
|
3334
Coya Therapeutics
COYA
$98.3M
| $80.5K | ﹤0.01% |
14,000
+1,800
| +15% | +$10.4K |
|
|
IMDX
3335
Insight Molecular Diagnostics
IMDX
$150M
| $78.8K | ﹤0.01% |
+26,100
| New | +$78.9K |
|
|
SBFM
3336
Sunshine Biopharma
SBFM
$2.78M
| $77.9K | ﹤0.01% |
+5,409
| New | +$79K |
|
3337
ClearOne Inc
CLRO
$10.9M
| $77.3K | ﹤0.01% |
13,447
-1,081
| -7% | -$7.52K |
|
|
SOHO
3338
DELISTED
Sotherly Hotels
SOHO
| $76.7K | ﹤0.01% |
80,714
+200
| +0.2% | +$158 |
|
3339
Alto Neuroscience
ANRO
$1.05B
| $76.3K | ﹤0.01% |
+34,700
| New | +$82.6K |
|
3340
Urban One Class A
UONE
$22.8M
| $75.5K | ﹤0.01% |
4,720
+10
| +0.2% | +$155 |
|
|
PCLA
3341
PicoCELA Inc
PCLA
$47.2M
| $74K | ﹤0.01% |
+1,523
| New | +$34K |
|
3342
Armata Pharmaceuticals
ARMP
$167M
| $73.9K | ﹤0.01% |
38,896
+300
| +0.8% | +$486 |
|
3343
Elutia
ELUT
$37.9M
| $73.3K | ﹤0.01% |
37,016
-700
| -2% | -$1.42K |
|
3344
Wrap Technologies
WRAP
$103M
| $73K | ﹤0.01% |
+46,800
| New | +$70.5K |
|
|
LONA
3345
LeonaBio Inc
LONA
$66.3M
| $72.8K | ﹤0.01% |
24,100
+2,200
| +10% | +$6.23K |
|
3346
Performance Shipping
PSHG
$21.6M
| $72.8K | ﹤0.01% |
41,584
+13,184
| +46% | +$20.7K |
|
|
SOGP
3347
Sound Group
SOGP
$50.3M
| $72K | ﹤0.01% |
15,158
| – | – |
|
|
INCR
3348
Intercure
INCR
$57M
| $71.9K | ﹤0.01% |
48,900
+500
| +1% | +$739 |
|
3349
Atlantic American Corp
AAME
$31.4M
| $71.1K | ﹤0.01% |
33,400
+300
| +0.9% | +$502 |
|
3350
Grove Collaborative
GROV
$46.2M
| $70.8K | ﹤0.01% |
61,600
+5,200
| +9% | +$6.15K |
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.